Posts tagged ‘drug discovery’
March 6th, 2011
Amgen’s denosumab has been shown to reduce skeletal related events (SRE) but not improve overall survival (OS) in prostate cancer.
Icarus Consultants’ oncology new product development expert, Sally Church Ph.D looks at the role of RANKL signaling (the target of denosumab) and recent research on its role in the spread of cancer.
You can gain more insight on this interesting topic from Sally’s Pharma Strategy Blog post.